supp.fit

Lutein, Meso-Zeaxanthin and Zeaxanthin: study protocols

16 study groups took Lutein together with Meso-Zeaxanthin and Zeaxanthin. These are the doses the studies gave. They are not a recommendation.

Lutein: what the research found →

Dose per serving from research: Lutein

16 study groups in 10 studies say how much Lutein participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 5 mg to 10 mg, 63% of 16 study groups.

Daily doseStudy groups
2.5 mg to 5 mg
4
5 mg to 10 mg
10
10 mg to 25 mg
2

Dose per serving from research: Meso-Zeaxanthin

15 study groups in 10 studies say how much Meso-Zeaxanthin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 5 mg to 10 mg, 73% of 15 study groups.

Daily doseStudy groups
5 mg to 10 mg
11
10 mg to 25 mg
4

Dose per serving from research: Zeaxanthin

16 study groups in 10 studies say how much Zeaxanthin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 mg to 2.5 mg, 88% of 16 study groups.

Daily doseStudy groups
1 mg or less
1
1 mg to 2.5 mg
14
over 2.5 mg
1

Commonly used together

3 of 16 study groups took Lutein, Meso-Zeaxanthin and Zeaxanthin with something else, but nothing that 3 or more different studies gave.

16 study groups

Study
Supplemental Retinal Carotenoids Enhance Memory in Healthy Individuals with Low Levels of Macular Pigment in A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
2018 · active group · Healthy individuals with low macular pigment levels; mean age 45.42 years, 51.6% male
10 mg10 mg2 mg1 year45
Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial
2022 · active group · Cognitively healthy adults aged 65 years and older
10 mg10 mg2 mg2 years30
Visual Function and Macular Carotenoid Changes in Eyes with Retinal Drusen-An Open Label Randomized Controlled Trial to Compare a Micronized Lipid-Based Carotenoid Liquid Supplementation and AREDS-2 Formula
2020 · LM group · Adults aged 54–80 with retinal drusen and risk of age-related macular degeneration
15 mg10 mg3 mg26 weeks29
Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment
2012 · Group 2 · Healthy subjects with atypical macular pigment spatial profiles; age and sex not stated
10 mg10 mg2 mg8 weeks10
Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment
2012 · Group 3 · Healthy subjects with atypical macular pigment spatial profiles; age and sex not stated
3 mg17 mg2 mg8 weeks10
Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration
2013 · Group 2 · Adults with or without age-related macular degeneration; age and sex not reported
10 mg10 mg2 mg8 weeks—
Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration
2013 · Group 3 · Adults with or without age-related macular degeneration; age and sex not reported
3 mg17 mg2 mg8 weeks—
Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease
2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported
10 mg10 mg2 mg1 year50
Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration
2014 · Group 2 · People with early age-related macular degeneration; age and sex not stated
10 mg10 mg2 mg1 year21
Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration
2014 · Group 3 · People with early age-related macular degeneration; age and sex not stated
3 mg17 mg2 mg1 year14
The impact of macular pigment augmentation on visual performance using different carotenoid formulations
2012 · group 2 · Adults, 19–64 years (mean age 51 years), 19 male and 17 female across the study; condition not specified
10 mg10 mg2 mg26 weeks—
The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial
2015 · Macushield, Alzheimer's disease patients · Adults with Alzheimer's disease; age range and sex not stated
10 mg10 mg2 mg26 weeks—
The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial
2015 · Macushield, age-similar control subjects · Age-similar control subjects; age range and sex not stated
10 mg10 mg2 mg26 weeks—
Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration
2015 · Group 1 · People with early age-related macular degeneration; age and sex not specified
20 mg—860 mcg3 years—
Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration
2015 · Group 2 · People with early age-related macular degeneration; age and sex not specified
10 mg10 mg2 mg3 years—
Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration
2015 · Group 3 · People with early age-related macular degeneration; age and sex not specified
3 mg17 mg2 mg3 years—
Lutein, Meso-Zeaxanthin and Zeaxanthin: study protocols | supp.fit